Atropo- and diastereoselective construction of tetracyclic biphenylazepinium salts derived from aminoalcohols: use as catalysts in enantioselective asymmetric epoxidation. by Philip C. Bulman Page (7128746) et al.
1 
 
Atropo- and diastereo- selective construction of tetracyclic biphenylazepinium salts 
derived from aminoalcohols: Use as catalysts in enantioselective asymmetric 
epoxidation  
 
Philip C. Bulman Page,a* Christopher A. Pearce,a Yohan Chan,a Phillip Parker,b Benjamin R. 
Buckley,b Gerasimos A. Rassias,c and Mark R. J. Elsegood b  
 
a School of Chemistry, University of East Anglia, Norwich Research Park, Norwich, Norfolk NR4 7TJ, UK  
b Chemistry Department, Loughborough University, Loughborough, Leicestershire LE11 3TU, UK  
c Department of Chemistry, University of Patras, 26504 Patras, Greece  
 
p.page@uea.ac.uk  
 
Abstract  
A range of new biphenylazepinium salt organocatalysts effective for asymmetric epoxidation has 
been developed incorporating an additional substituted oxazolidine ring, and providing improved 
enantiocontrol in alkene epoxidation over the parent structure. Starting from enantiomerically pure 
amino-alcohols, tetracyclic iminium salts were obtained as single diastereoisomers through an 
atroposelective oxazolidine formation.  
 
Introduction  
Epoxides are versatile building blocks widely used in synthesis.1 The past thirty years have seen the 
development of many methodologies capable of efficient asymmetric epoxidation of various types of 
alkene.2 Dioxiranes,3 and oxaziridinium salts, first reported by Lusinchi,4 and generated in situ from 
the corresponding iminium salts5 or amines,6 have proven to be two of the most effective types of 
organocatalyst for asymmetric oxygen transfer to weakly nucleophilic substrates such as 
unfunctionalized alkenes. Over the past ten years we have developed a range of enantiopure iminium 
salts effective as organocatalysts for highly enantioselective asymmetric epoxidation in the presence 
of Oxone as stoicheiometric oxidant. We have reported that the most reactive and selective iminium 
salt catalysts discovered to date are based on (S,S)-acetonamine derivative 1 and a biphenyl 
backbone such as 2, 3 and 4, or a binaphthyl backbone such as 5. For example, iminium species 2a 
catalyses the oxidation of 1-phenylcyclohexene to its corresponding epoxide in less than 4 minutes 
inducing up to 60% enantioselectivity,7 while catalyst 5a affords the same epoxide in 91% ee after 15 
min.8 The use of alternative oxidants, such as bleach or hydrogen peroxide, has also been explored,9 
and the successful development of non-aqueous conditions using tetraphenylphosphonium 
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monoperoxysulfate10 (TPPP) has allowed us to access highly enantioenriched epoxides (up to 99% 
ee).11  
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Figure 1. Iminium salt catalysts for asymmetric epoxidation  
 
A potential issue concerning cyclic biaryl structures is their ability to rotate through the aryl/aryl 
bond generating two interconverting atropoisomers.12 Using biaryl azepine 6 as a model substrate, 
Wallace showed that asymmetric introduction of an alkyl group at C(7) could induce a strong 
conformational preference for one atropoisomer.13 Lacour has used derivatization at the 3,3’-
positions on the aromatic rings to prevent such interconversion, as in 3a/3b.14 We have shown that 
the introduction of an axial substituent at the C(7) position by nucleophilic addition to 2a to create a 
new chiral centre adjacent to the iminium nitrogen, followed by reoxidation, generates ‘second 
generation’ iminium salt catalysts such as 2b, 3b, 4b and 5b, which provide increased enantiocontrol 
in the epoxidation of alkene substrates.15  
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Meyers’ bicyclic lactam methodology has been widely used in the stereoselective construction of 
five-, six- and seven-membered ring nitrogen heterocycles from enantiopure amino alcohols.16 
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Particularly of interest to us, the methodology has been applied to prepare a range of axially chiral 
biaryl lactams such as 7.17 We postulated that structurally related iminium salts such as 8 might 
impart increased levels of enantioselectivity when used as an asymmetric epoxidation catalyst by 
imparting additional rigidity and structural elements in the transition state compared to catalysts such 
as 4.  
 
Results and Discussion 
Our initial hypothesis was that the 7,5-fused bicyclic lactam sub-structure 7 could be used to 
generate amine 9, a suitable precursor to iminium species 8, by reduction of the lactam unit (Scheme 
1). However, reduction of compound 7 is known to lead to amino-alcohol 10 using literature 
procedures.18 We have previously shown that oxidation of such azepines occurs preferentially at the 
least substituted adjacent position, ruling out the possibility to use this pathway, because 10 would 
not be oxidized to 11.15 We therefore devised an alternative pathway based upon a biaryl coupling of 
a suitably functionalized oxazolidinone using an adaptation of Fagnou’s methodology19 by Wallace 
(Scheme 1).20 Synthesis of the cyclization precursor 12 would be achieved by Suzuki-Miyaura 
coupling of a suitably functionalized amino-alcohol 14 with 2-acetylphenylboronic acid to give 13, 
and subsequent hydrolysis of the oxazolidinone protecting group. Cyclocondensation of 12 to form 
the iminium species 11 would result in concomitant cyclization to the oxazolidine 9 by 
intramolecular attack of the hydroxyl group. We have previously observed diastereoselective 
formation of oxazolidines in a related binaphthyl system when generating iminium species bearing 
an alcohol moiety.21 Finally, oxidation of 9 under our standard conditions would give iminium salt 
catalyst 8.  
 
This methodology would allow the use of a wide variety of enantiomerically pure amino-alcohol 
precursors. Accordingly, alkylation of (R)-phenyl oxazolidinone 15 with 2-iodobenzylbromide 
afforded N-substituted oxazolidinone 14 in 98% yield. N-Benzyl oxazolidinone 14 was coupled with 
2-acetylphenyl boronic acid under conditions used by Levacher.17a Hydrolysis of the crude 
oxazolidinone 13 was completed with aqueous sodium hydroxide in dichloromethane; the solvent 
was removed and tert-butylmethyl ether (TBME) added. The resulting solution of aminoalcohol 12 
was treated with aqueous HCl to generate the desired tetracyclic amine 9 via 11 as a single 
diastereoisomer in 12% yield over the three steps. Finally, the iminium salt 8 was generated by 
oxidation of the amine using NBS in chloroform in 80% yield.  
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Scheme 1  
 
We tested iminium salt 8 for its efficacy as an epoxidation catalyst, using 1-phenylcyclohexene as 
our test substrate under our standard Oxone oxidative conditions. Catalyst 8 gave 100% conversion 
within thirty minutes, imparting a fair 55% ee for 1-phenylcyclohexene oxide (Scheme 2).  
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Scheme 2  
 
While this result established a new sub-structure of iminium salts active for the catalytic asymmetric 
epoxidation of alkenes, the overall yield of this synthetic route, particularly in the conversion of 14 
into 9, coupled with the problematic purification of the unstable oxazolidinone 13 led us to seek an 
alternative.  
 
We reasoned that a change of aminoalcohol protecting group from oxazolidinone to a much more 
readily hydrolysed oxaminal might improve the process, and so targeted dimethyloxazolidine 18 
(Scheme 3). Reductive amination of 2-iodobenzaldehyde with (R)-phenyl glycinol 16 gave the N-
benzyl amino alcohol 17 in 81% yield. Protection of the aminoalcohol functionality with 
dimethoxypropane gave the oxazolidine 18 in 96% yield.  
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Scheme 3  
 
Oxazolidine 18 was coupled with 2-acetylphenylboronic acid under the conditions described above. 
Attempted purification using column chromatography on silica gel of the crude coupled product led 
to the isolation of a mixture of two inseparable compounds. Upon inspection of the 1H NMR 
spectrum of the mixture, the two products were identified as the desired Suzuki adduct 19 and the 
target tetracyclic 6,6,7,5 material 9 as a single diastereoisomer.  
 
Following our conjecture that silica gel had effected a deprotection to expose the aminoalcohol, 
which then condensed in situ with the pendent ketone generating the desired tetracycle, we subjected 
the crude reaction mixture from the Suzuki coupling to silica gel in chloroform over 15 h (Scheme 
3), so generating tetracycle 9 as a single diastereoisomer in a somewhat improved 40% yield. The 
absolute configuration of 9 was confirmed by single crystal X-ray analysis. The tetracylic tertiary 
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amine 9 was readily converted into iminium salt 8 in 80% yield. To test the need for the 
protection/deprotection steps, a Suzuki coupling between unprotected amino-alcohol 17 and 2-
acetylphenylboronic acid was attempted. 
 
Anticipating the deactivation of the palladium-phosphine catalyst by the aminoalcohol, we expected 
to observe poor conversion. To our delight, however, we observed the Suzuki coupling followed by 
in situ intramolecular cyclization, generating the 6,6,7,5-tetracyclic core 9 as a single 
diastereoisomer in 40% yield (Scheme 4). 
  
Scheme 4  
 
The phenyl substituted azepinium bromide salt 8 was thus obtained in just four steps in 26% overall 
yield from (R)-phenyl glycinol 16. A number of aminoalcohols - (S)-alaninol, (S)-valinol, and (R)- & 
(S)-phenylalaninol - were subjected to the same reaction sequence to prepare a selection of potential 
catalysts with different substituents at the oxazolidine ring, to give the cyclized products 8 and 28-
31, each again generated as single diastereoisomers (Table 1; Figure 2).  
  
Table 1. Isolated yields of the key intermediates in generating six tetracyclic iminium salt catalysts  
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R = (S)-Me 83% (20) 22% (24) 74% (28) 
R = (S)-iPr 16% (21) 47% (25) 81% (29) 
R = (R)-Ph 81% (17) 40% (9) 80% (8) 
R = (R)-Bn 90% (22) 60% (26) 82% (30) 
R = (S)-Bn 86% (23) 30% (27) 75% (31) 
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Figure 2. New iminium salts  
 
Single crystal X-ray structure determination carried out on the (R)-phenyl 9 and (S)-benzyl 27 
derivatives (Figure 3) show the cis-relationship between the methyl groups and the oxazolidine ring 
phenyl and benzyl substituents derived from the parent aminoalcohols, the pseudo-equatorial 
placement of these phenyl and benzyl substituents, the axial orientation of the methyl groups, and the 
chirality of the atropoisomeric biaryl units.  
 
(aR,3R,13bS)-amine 9 (aS,3S,13bR)-amine 27  
Figure 3. Single crystal X-ray structural determination of 9 and 27  
 
The stereoselectivity of the cyclization of the aminoalcohol functionality in the intermediate iminium 
species 11 may be driven by preferred placement of the smaller methyl substituent in the pseudo-
axial orientation (Scheme 5), perhaps through an equilibrium process.17a  
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Scheme 5  
 
Catalysts 8 and 28-31 were tested for catalytic activity under our standard conditions using oxone as 
oxidant, and compared to the simple biphenyl azepinium catalyst 2a (Table 2).  
 
Table 2. Asymmetric Epoxidation of a range of alkenes by catalysts 8 and 28-31a  
Epoxide Catalyst Conversion/% c, d ee/% b, c Major enantiomer f 
O
 
2a 100 60 (–)-1S,2S 
8 100 55 (+)1R,2R 
28 100 30 (–)-1S,2S 
29 100 30 (–)-1S,2S 
30 100 64 (+)1R,2R 
31 100 64 (–)-1S,2S 
O
 
2a 100 32 (+)1S,2R 
8 100 76 (–)1R,2S 
30 100 46 (–)1R,2S 
31 100 47 (+)1S,2R 
O
 
2a 34 41 (–)1R,2S 
8 20 64 (+)1S,2R 
30 47 52 (+)1S,2R 
31 39 55 (–)1R,2S 
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O
 
2a 90 15 (–)1S,2S 
8 100 22 (+)1R,2R 
30 98 18 (+)1R,2R 
31 95 13 (–)1S,2S 
O
 
2a 90 24 (–)1S 
8 100 30 (+1R 
30 100 23 (+)1R 
31 100 19 (–)1S 
a Epoxidation conditions: Iminium salt catalyst (5 mol%), Oxone® (2 equiv.). Na2CO3 (4 equiv.), MeCN:H2O 1:1 (5 ml), 
0 ºC, 1-6 h. b Enantiomeric excesses were determined by chiral GC chromatography on a Chiraldex B-DM column by 
comparison of the two epoxide peak areas. c Conversions were evaluated from the chiral GC–FID spectra by comparison 
of the alkene and epoxide peak areas. d Enantiomeric excess determined by Chiral HPLC on a Chiracel OD-H column. e 
Conversions were evaluated from the 1H-NMR spectra by integration of alkene and epoxide signals. f Absolute 
configurations of the major enantiomers were determined by comparison of both optical rotation and GC-FID of samples 
of known configuration.  
 
Catalysts 8, 30, and 31 provide greater enantioselectivity in the oxidation of 1-phenylcyclohexene 
than catalysts 28 and 29, and this pattern is repeated for the other alkene substrates tested. Observed 
enantioselectivities are comparable with or superior to the simple azepinium catalyst 3a. Highest 
enantioselectivities were observed with the cyclic cis-alkene dihydronaphthalene substrates, where 
catalysts 8, 30, and 31 outperformed catalyst 2a by a considerable margin.  
 
Conclusion  
To conclude, we have successfully developed a new sub-structure of iminium salt catalyst containing 
a 6,6,7,5-ring tetracyclic core. The synthesis of these novel iminium salts can be completed within 
four steps in good yields from the corresponding amino-alcohols. We have postulated that the 
cyclization occurs through one favoured atropoisomer, giving rise to a favoured diastereoisomer in 
all the iminium salt catalysts generated, that where the methyl group is pseudo-axial. Catalysts 8, 30 
and 31 generally provide enantioselectivities better than or equal to the parent azepinium catalyst 2a.  
 
Experimental Section  
General Experimental Detail  
All infrared spectra were obtained using; thin films on sodium chloride plates. All 1H and 13C NMR 
spectra were measured at 400.13 and 100.62 MHz respectively, or at 500.21 and 125.79 MHz 
respectively, in deuteriochloroform solution unless otherwise stated, using TMS (tetramethylsilane) 
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as the internal reference. Mass spectra were recorded utilizing electron–impact (EI), fast atom 
bombardment (FAB) or electrospray (ESI) techniques and an ion trap mass analyser. Optical rotation 
values were measured at λ=589 nm, corresponding to the sodium D line, at the temperatures 
indicated. All chromatographic manipulations used silica gel as the adsorbent. Reactions were 
monitored using thin layer chromatography (TLC) on aluminium–backed plates coated with F254 
silica gel. TLC plates were visualized by UV irradiation at a wavelength of 254 nm, or stained by 
exposure to an ethanolic solution of phosphomolybdic acid (acidified with concentrated sulfuric 
acid), followed by charring where appropriate. Reactions requiring anhydrous conditions were 
carried out using glassware dried overnight at 150 ºC, under a nitrogen atmosphere unless otherwise 
stated. Reaction solvents were used as obtained commercially unless otherwise stated. Light 
petroleum (b.p. 40–60 ºC) was distilled from calcium chloride prior to use. Ethyl acetate was 
distilled over calcium chloride. Dichloromethane was distilled over calcium hydride. 
Tetrahydrofuran and diethyl ether were distilled under a nitrogen atmosphere from the 
sodium/benzophenone ketyl radical. Acetone was dried over 4Å Linde molecular sieve, and distilled 
under a nitrogen atmosphere. Enantiomeric excesses were determined by chiral HPLC using a 
Chiracel OD and OD-H columns with an ultra–violet absorption detector set at 254 nm, by chiral GC 
using a Chiraldex B-DM column and a flame ionization detector, or by proton nuclear magnetic 
resonance spectroscopy in the presence of europium (III) tris[3–
(heptafluropropylhydroxymethylene)–(+)–camphorate] as the chiral shift reagent.  
 
General procedure A: Reductive amination using 2-iodobenzaldehyde and aminoalcohols  
The amino alcohol and 2-iodobenzaldehyde (1.1 equiv.) were dissolved in methanol (10 mL per g of 
aminoalcohol) and agitated over 5 to 16 h. The mixture was cooled to 0 °C, sodium 
cyanoborohydride (1.1 equiv.) added, and the mixture stirred at ambient temperature for 16 h. 
Saturated aqueous ammonium chloride (1 mL per g of aminoalcohol) was added and the solvent 
removed under reduced pressure. The residue was dissolved in tert-butyl methyl ether (10 mL per g 
of aminoalcohol) and the solution washed with saturated brine and dried over magnesium sulphate. 
The solvents were removed and the crude oil purified by column chromatography using 
CH2Cl2/MeOH (100:0-95:5) as eluent to yield the desired secondary amine.  
 
General procedure B: Suzuki coupling between 2-iodobenzyl aminoalcohols and 2-acetyl 
phenylboronic acid  
The aminoalcohol and 2-acetyl phenylboronic acid (3 equiv.) were dissolved in toluene (10 mL per g 
of aminoalcohol) and ethanol (1 mL per g of aminoalcohol) and saturated aqueous potassium 
carbonate (1 mL per g of aminoalcohol) added. The mixture was degassed with nitrogen over 30 
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min. Pd(PPh3)4 (10 mol%) was added and the mixture degassed for a further 15 min. The mixture 
was stirred at reflux under a nitrogen atmosphere with monitoring by HPLC; once complete 
consumption of the starting material was observed, the mixture was allowed to cool to ambient 
temperature and filtered through a plug of celite. The organic layer was separated, washed with 
water, dried over magnesium sulphate, and the solvents were removed under reduced pressure. The 
residue was dissolved in chloroform (10 mL per g of aminoalcohol and silica gel (0.5 g per g of 
aminoalcohol) added. The mixture was stirred for 15 hours at room temperature to achieve 
cyclization. The suspension was filtered through a plug of celite and the solvent removed under 
reduced pressure. The residue was purified using flash chromatography on silica gel using ethyl 
acetate:heptane (1-5%) as eluent.  
 
General procedure C: Oxidation of tertiary cyclic amines using N-bromosuccinimide  
The amine was dissolved in chloroform (5 mL per g of amine) and the mixture cooled to 0 °C. N-
Bromosuccinimide (2 equiv.) was added. The reaction mixture was removed from the ice bath and 
stirred for 15-20 min with monitoring by HPLC/TLC. Upon completion, water (10 mL per g of 
amine) was added, and the organic layer separated and dried over magnesium sulphate. The solvent 
was removed under reduced pressure to yield the corresponding bromide salt. The residue was 
dissolved in ethanol (50 mL per g of bromide salt) and a solution of sodium tetraphenylborate (1 
equiv.) in the minimum amount of acetonitrile to enable dissolution added. The solvents were 
removed under reduced pressure and the residue was recrystallized from ethanol to yield the desired 
tetracyclic imnium tetraphenylborate salts.  
 
General procedure for the formation of racemic epoxides for ee determinations  
The alkene was dissolved in dichloromethane (10 mL per g of alkene) and cooled to 0 ºC. m-CPBA 
(2 equiv.) was added as a solution in dichloromethane (10 mL per g of alkene). The mixture was 
allowed to attain ambient temperature and stirred until complete consumption of the substrate was 
observed by TLC. Saturated aqueous NaHCO3 (20 mL per g of alkene) was added and the layers 
separated. The organic layer was washed with NaOH (1.0 M, 20 mL per g of alkene), and dried 
(MgSO4). The solvents were removed under reduced pressure and the product purified by column 
chromatography, eluting with ethyl acetate/light petroleum (1:99).  
 
General procedure for catalytic asymmetric epoxidation of simple alkenes mediated by 
iminium salts using Oxone  
Oxone (2 equiv.) was added to an ice cooled solution of Na2CO3, (4 equiv.) in water (8 mL per g of 
Na2CO3), and the resulting foaming solution stirred for 5-10 min. The iminium salt (10 mol%) was 
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added as a solution in acetonitrile (4 mL per g of Na2CO3 used), followed by the alkene substrate, 
also as a solution in acetonitrile (4 mL per g of Na2CO3 used). The mixture was stirred at 0 °C until 
the alkene substrate was completely consumed as observed by TLC. The mixture was dissolved in 
ice-cooled diethyl ether (20 mL per 100 mg substrate), and the same volume of water added. The 
aqueous phase was washed four times with diethyl ether, and the combined organic layers were 
washed with saturated brine and dried over magnesium sulphate. Filtration and evaporation of the 
solvents gave a yellow/brown residue, which was purified by column chromatography, eluting with 
ethyl acetate/light petroleum (1:99).  
 
3-(2’-Iodobenzyl)-4R-phenyloxazolidin-2-one 14  
 (R)-(–)-4-phenyl-2-oxazolidinone (0.20 g, 1.23 mmol, 1.0 equiv.) was dissolved in THF (2 mL) at 
room temperature under a nitrogen atmosphere. NaHMDS (2M in THF, 0.68 mL, 1.35 mmol, 1.1 
equiv.) was added and the reaction mixture stirred for 30 min. A solution of 2-iodobenzylbromide 
(0.40 g, 1.35 mmol, 1.1 equiv.) in THF (2 mL) was added and the reaction monitored by HPLC. On 
complete consumption of the starting material, saturated aqueous potassium carbonate (10 mL per g 
of oxazolidinone) and tert-butyl methyl ether (20 mL per g of oxazolidinone) were added. The 
organic layer was separated, washed with brine (10 mL per g of oxazolidinone), dried over 
anhydrous magnesium sulphate, and the solvents removed under reduced pressure to yield the 
desired alkylated oxazolidinone (0.46 g, 1.21 mmol, 98%); νmax(film) /cm-1 2960, 1749, 1428, 1240, 
1081, 1012, 751, 668. [α]20D −7.8 ° (c 1.0, CH2Cl2), 1H NMR (400 MHz; CDCl3) δH 4.00 (1 H, d, J 
15.6 Hz), 4.17 (1 H, dd. J 5.6, 8.4 Hz), 4.56 (1 H, dd, J 5.2, 9.2 Hz), 4.63 (1 H, t, J 8.3 Hz), 4.80 (1 
H, d, J 15.4 Hz), 6.97 (1 H, td, J 1.5, 7.5 Hz), 7.14 - 7.20 (3 H, m), 7.29 (1 H, td,  J 1.2, 7.5 Hz), 7.35 
- 7.40 (3 H, m), 7.79 (1 H, dd, J 1.2, 7.9 Hz). 13C NMR (100 MHz; CHCl3) δC 50.7, 59.3, 70.1, 99.0, 
127.2, 128.6, 129.2, 129.4, 129.7, 130.0, 137.8, 137.9, 140.0, 158.4; m/z found for [M+H]+ 
380.0145; [C16H14NO2I+H]+ requires 380.0142.  
 
2-(2’-Iodobenzylamino)-2(R)-phenylethanol 17  
(R)-Phenylglycinol (1.32 g, 9.60 mmol, 1.1 equiv.) in MeOH (25 mL), 2-iodobenzaldehyde (2.20 g, 
9.50 mmol, 1.0 equiv.) and NaBH3CN (0.60 g, 9.60 mmol, 1.1 equiv.) were treated using general 
procedure A to yield the desired product (2.77 g, 7.80 mmol, 81%); [α]20D −49.7 ° (c 1.0, CH2Cl2). 
1H NMR (400 MHz; CDCl3) δH 3.58 (1 H, dd, J 8.6, 10.8 Hz), 3.66 (1 H, d, J 13.2 Hz), 3.73 (1 H, 
dd, J 4.4, 10.8 Hz), 3.78 (1 H, d, J 13.2 Hz), 3.81 (1 H, dd, J 4.4, 8.4 Hz), 6.93-6.98 (1 H, m), 7.26-
7.40 (7 H, m), 7.80-7.83 (1 H, m); 13C NMR (100 MHz; CHCl3) δC 55.8, 64.0, 67.0, 100.0, 127.5, 
127.9, 128.4, 128.8, 129.1, 130.2, 139.8, 140.3, 142.2; m/z found for [M+H]+: 354.0363; 
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[C15H16INO+H]+ requires 354.0355.  
 
3-(2’-Iodobenzyl)-2,2-dimethyl-(4R)-phenyloxazolidine 18  
 (2R)-2-(2’-Iodo-benzylamino)-2-phenyl-ethanol 17 (650 mg, 1.84 mmol, 1 equiv.) was dissolved in 
toluene (10 mL). Dimethoxypropane (2.25 mL, 18.40 mmol, 10 equiv.) and p-TSA (70.0 mg, 0.37 
mmol, 0.2 equiv.) were added, and the mixture heated under reflux using a Dean-Stark apparatus. 
The reaction was monitored by TLC and the azeotropic removal of solvents. Upon completion, the 
mixture was allowed to reach ambient temperature. Saturated brine (3 x 20 mL) was added and the 
organic phase separated, dried over MgSO4, and the solvents removed under reduced pressure. 
Purification using column chromatography on silica gel (washed with 4% TEA) using 
ethylacetate/light petroleum (10%) as eluent yielded the desired acetal as a yellow low-melting solid 
(694 mg, 1.76 mmol, 96%); νmax(film) /cm-1 3420, 2972, 1455, 1362, 1255, 1187, 1054, 1011, 753, 
700; [α]20D −60.2 (c 1.19, CHCl3); 1H NMR (400 MHz; CDCl3) δH 1.34 (3 H, s), 1.37 (3 H, s), 3.67 
(1 H,d, J 14.4 Hz), 3.75 (1 H, t, J 8.0 Hz), 3.88 (1 H, d, J 14.8 Hz), 4.08 (1 H, t, J 7.6 Hz), 4.21 (1 H, 
t, J 7.2 Hz), 6.75 (1 H, dt, J 1.6, 7.6 Hz), 7.09-7.14 (2 H, m), 7.15-7.20 (2 H, m), 7.32-7.36 (2 H, m), 
7.43 (1 H, dd, J 1.6, 7.6 Hz), 7.61 (1 H, dd, J 1.2, 8.0 Hz); 13C NMR (100 MHz; CHCl3) δC 21.6, 
28.7, 56.8, 67.8, 72.1, 96.4, 99.6, 127.5, 127.7, 128.1, 128.2, 128.5, 131.3, 139.1, 140.5, 141.2; m/z 
found for M+: 393.0583; [C18H20INO]+ requires 393.0590.  
 
(aR,3R,13bS)-13b-Methyl-3-phenyl-2,3-dihydro-13bH-dibenz[c,e]oxazolo[3,2-a]azepine 9  
First method: from oxazolidinone 14 
(4R)-3-(2’-Iodo-benzyl)-4-phenyl-oxazolidin-2-one 14 (0.46 g, 1.21 mmol) was dissolved in toluene 
(5 mL) and ethanol (7.5 mL). 2-Acetyl phenylboronic acid (0.20 g, 1.21 mmol, 1 equiv.) and 
saturated aqueous potassium carbonate (5 mL) were added. The mixture was degassed with nitrogen 
over 30 min. Pd(PPh3)4 (0.07 g, 0.06 mmol, 5 mol%) was added, and the mixture was degassed with 
nitrogen for a further 15 min. The mixture was stirred under reflux under a nitrogen atmosphere with 
monitoring by HPLC. Once complete consumption of the starting material was observed, the mixture 
was allowed to cool to ambient temperature. The mixture was filtered through a plug of celite, and 
the solvents were removed under reduced pressure. tert-Butyl methyl ether (10 mL) and water (5 
mL) were added to the residue. The organic layer was separated, washed with water (5 mL), and 
dried over MgSO4. The solvents were removed under reduced pressure, and the residue dissolved in 
ethanol (5 mL) and aqueous NaOH (2M, 5 mL) added. The mixture was heated under reflux for 16 h 
to remove the protecting goup, then allowed to cool to ambient temperature. The organic solvent was 
removed under reduced pressure, the residue was dissolved in tert-butyl methyl ether (5 mL), and 
aqueous HCl (5M, 1 mL) added. The mixture was stirred for 30 min to achieve cyclization, and the 
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organic layer separated, dried over magnesium sulphate and the solvents removed under reduced 
pressure. The residue was purified using flash chromatography on silica gel using ethyl 
acetate:heptane (1 – 5%) as eluent to give the desired product (0.049 g, 0.15 mmol, 12%).  
 
Second method: from oxazolidine 18  
(4R)-3-(2-Iodo-benzyl)-2,2-dimethyl-4-phenyl-oxazolidine 18 (0.69 g, 1.76 mmol) was dissolved in 
toluene (10 mL) and ethanol (15 mL). 2-Acetyl phenylboronic acid (0.29 g, 1.76 mmol, 1 equiv.) and 
saturated aqueous potassium carbonate (10 mL) were added. The mixture was degassed with 
nitrogen over 30 min. Pd(PPh3)4 (0.10 g, 0.09 mmol, 5 mol%) was added, and the mixture degassed 
with nitrogen for a further 15 min. The mixture was stirred under reflux under a nitrogen atmosphere 
for 4 h. The mixture was allowed to cool to ambient temperature, filtered through a plug of celite, 
and the solvents were removed under reduced pressure. tert-Butyl methyl ether (10 mL) and water (5 
mL) were added to the residue. The organic layer was separated, washed with water (5 mL) and 
dried over MgSO4. The solvents were removed under reduced pressure, and the residue dissolved in 
chloroform (10 mL) and silica gel added. The mixture was stirred at room temperature for 30 min 
and the suspension filtered through a pad of celite. The solvent was removed under reduced pressure 
and the residue purified using flash chromatography on silica gel using ethyl acetate:heptane (1-5%) 
as eluent to give the desired product (0.23 g, 0.70 mmol, 40%).  
 
Third method: from amino alcohol 17  
 (2R)-(2’-Iodobenzylamino)-2-phenylethanol 17 (2.29 g, 6.50 mmol) and 2-acetyl phenylboronic 
acid (3.20 g, 19.5 mmol, 3 equiv.) were treated using general procedure B to yield the desired 
product (0.85 g, 2.60 mmol, 40%); νmax(film) /cm-1 2963, 1449, 1260, 1153, 1038, 897, 802, 758, 
740, 701. [α]20D –15.6° (c 1.0, CH2Cl2). 1H NMR (400 MHz; CDCl3) δH 1.11 (3 H, s), 3.09 (1 H, d, J 
10.8 Hz), 3.58 (1 H, d, J 10.8 Hz), 3.86 (1 H, dd, J 7.6, 9.2 Hz), 3.94 (1 H, dd, J 6.0, 9.6 Hz), 4.37 (1 
H, t, J 6.8 Hz), 7.25 (1 H, d, J 6.8 Hz), 7.30-7.37 (2 H, m), 7.38-7.45 (3 H, m), 7.46-7.53 (6 H, m), 
7.86-7.92 (1 H, m); 13C NMR (100 MHz; CHCl3) δC 30.6, 52.5, 69.3, 72.8, 97.3, 125.8, 127.6, 127.8, 
127.9, 128.00, 128.04, 128.1, 128.5, 128.8, 129.1, 128.2, 135.3, 137.0, 139.1, 140.4, 142.1; m/z 
found for M+ 327.1626; [C23H21NO]+ requires 327.1623.  
 
2S-(2’-Iodobenzylamino)-propan-1-ol 20  
 (S)-Alaninol (1.3 mL, 16.38 mmol) and 2-iodobenzaldehyde (3.8 g, 16.38 mmol, 1 equiv.) were 
dissolved in toluene (100 mL) in a round-bottomed flask fitted with a Dean-Stark apparatus. Acetic 
acid (0.5 mL) was added and the solution heated under reflux for 16 h. The reaction mixture was 
allowed to reach room temperature and the solvents were removed under reduced pressure. The 
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residue was dissolved in methanol (50 mL), NaBH3CN (1.23 g, 19.66 mmol, 1.2 equiv.) and acetic 
acid (1 mL) were added, and the solution was stirred for 16 h. Saturated aqueous NH4Cl (20 mL) 
was added, and the aqueous layer washed with Et2O (3 x 20 mL). The combined organic layers were 
washed with a saturated solution of aqueous NH4Cl (20 mL). The aqueous layers were combined and 
the pH of the solution was brought to 8-9 using a saturated solution of Na2CO3. The resulting 
solution was extracted using dichloromethane (3 x 20 mL) and the combined organic layers were 
washed with water and brine, dried over MgSO4, filtered, and the solvents removed to yield the 
product (4.0 g, 13.75 mmol, 83%); νmax(film) /cm-1 3324, 2956, 1563, 1435, 1045, 1011, 750, 648. 
[α]20D +10.8 ° (c 1.0, CH2Cl2). 1H NMR (500 MHz; CDCl3) δH 1.08 (3 H, d, J 6.0 Hz), 2.78-2.85 (1 
H, m), 3.29 (1 H, dd, J 7.0, 11.0 Hz), 3.58 (1 H, dd, J 4.0, 11.0 Hz), 3.74 (1 H, d, J 13.5 Hz), 3.87 (1 
H, d, J 13.5 Hz), 6.94 (1 H, dt, J 1.5, 7.5 Hz), 7.30 (1 H, dt, J 1.0, 7.5 Hz), 7.35 (1 H, dd, J 1.5, 7.5 
Hz), 7.81 (1 H, dd, J 1.2, 8.0 Hz). 13C NMR (125 MHz; CHCl3) δC 17.1, 53.9, 55.6, 65.6, 99.8, 
128.4, 129.0, 129.8, 139.6, 142.2; m/z found for [M+H]+: 292.0204; [C10H14NOI+H]+ requires 
292.0198.  
 
2S-(2’-Iodobenzylamino)-3-methyl-butan-1-ol 21  
 (S)-Valinol (2.56 g, 24.8 mmol) in MeOH (50 mL), 2-iodobenzaldehyde (6.33 g, 27.3 mmol, 1.1 
equiv.) and NaBH3CN (1.71 g, 27.3 mmol, 1.1 equiv.) were treated using general procedure A to 
yield the product (1.30 g, 4.09 mmol, 16%); νmax(film) /cm-1 3321, 2956, 1563, 1464, 1435, 1045, 
1011, 750, 648. [α]20D −16.7 ° (c 1.5, CHCl3). 1H NMR (400 MHz; CDCl3) δH 0.93 (3 H, d, J 6.8 
Hz), 0.99 (3 H, d, J 6.8 Hz), 1.81 (1 H, sextet, J 6.8 Hz), 2.41 (1 H, dt, J 4.0, 6.4 Hz), 3.40 (1 H, dd J 
6.8, 10.8 Hz), 3.68 (1 H, dd, J 4.0, 10.8 Hz), 3.78 (1 H, d, J 13.2 Hz), 3.88 (1 H, d, J 13.2 Hz), 6.97 
(1 H, dt, J 2.0, 7.6 Hz), 7.32 (1 H, dt, J 1.2, 7.2 Hz), 7.36 (1 H, dd, J 1.6, 7.6 Hz), 7.83 (1 H, dd, J 
0.8, 8.0 Hz); 13C NMR (100 MHz; CHCl3) δC 18.7, 19.8, 29.1, 56.0, 60.6, 64.1, 100.0, 128.6, 129.2, 
130.1, 139.7, 142.5; m/z found for [M+H]+ 320.0511; [C12H18INO+H]+ requires 320.0511.  
 
2R-(2’-Iodobenzylamino)-3-phenyl-propan-1-ol 22  
 (2R)-2-Amino-3-phenylpropan-1-ol (2.92 g, 19.6 mmol) in MeOH (50 mL), 2-iodobenzaldehyde 
(3.00 g, 21.5 mmol, 1.1 equiv.) and NaBH3CN (1.35 g, 21.5 mmol, 1.1 equiv.) were treated using 
general procedure A to yield the product (6.47 g, 17.6 mmol, 90%); νmax(film) /cm-1 3441, 2359, 
1652, 1635, 1113, 743, 699, 668. [α]20D +20.0° (c 1.5, CHCl3). 1H NMR (400 MHz; CDCl3) δH 2.81 
(2 H, qd, J 7.2, 14.0 Hz), 2.93-3.00 (1 H, m), 3.38 (1 H, dd, J 5.2, 10.8 Hz), 3.71 (1 H, dd, J 4.0, 10.8 
Hz), 3.80 (2 H, s), 6.95 (1 H, dt, J 1.6, 7.6 Hz), 7.14-7.18 (2 H, m), 7.19-7.24 (2 H, m), 7.25-7.31 (3 
H, m), 7.79 (1 H, dd, J 1.2, 8.0 Hz); 13C NMR (100 MHz; CHCl3) δC 38.4, 55.7, 59.5, 62.6, 100.0, 
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126.7, 128.5, 128.8, 129.2, 129.4, 129.9, 138.4, 139.7, 142.0; m/z found for [M+H]+ 368.0506; 
[C16H18NOI+H]+ requires 368.0510.  
 
2S-(2’-Iodobenzylamino)-3-phenyl-propan-1-ol 23  
(2S)-2-Amino-3-phenylpropan-1-ol (2.92 g, 19.6 mmol) in MeOH (50 mL), 2-iodobenzaldehyde 
(3.00 g, 21.5 mmol, 1.1 equiv.) and NaBH3CN (1.35 g, 21.5 mmol, 1.1 equiv.) were treated using 
general procedure A to yield the product (6.19 g, 16.9 mmol, 86%); νmax(film) /cm-1 3450, 2358, 
1645, 1112, 745, 670, 668. [α]20D −22.8° (c 1.3, CHCl3). 1H NMR (400 MHz; CDCl3) δH 2.81 (2 H, 
qd, J 7.2, 14.0 Hz), 2.93-3.00 (1 H, m), 3.38 (1 H, dd, J 5.2, 10.8 Hz), 3.70 (1 H, dd, J 3.6, 10.8 Hz), 
3.80 (2 H, s), 6.95 (1 H, dt, J 2.0, 8.0 Hz), 7.14-7.18 (2 H, m), 7.19-7.24 (2 H, m), 7.26-7.31 (3 H, 
m), 7.79 (1 H, dd, J 1.2, 8.0 Hz); 13C NMR (100 MHz; CHCl3) δC 38.4, 55.7, 59.5, 62.7, 100.0, 
126.7, 128.5, 128.8, 129.1, 129.4, 129.9, 138.4, 139.7, 142.0; m/z found for [M+H]+ 368.0506; 
[C16H18INO+H]+ requires 368.0510.  
 
(aS,3S,13bR)-3,13b-Dimethyl-2,3-dihydro-13bH-dibenz[c,e]oxazolo[3,2-a]azepine 24  
 (2S)-2-(2’-Iodo-benzylamino)-propan-1-ol 20 (1.05 g, 3.60 mmol) and 2-acetyl phenylboronic acid 
(1.77 g, 10.8 mmol, 3 equiv.) were treated using general procedure B to yield the product (0.21 g, 
0.80 mmol, 22%); νmax(film) /cm-1 3377, 2966, 1448, 1365, 1217, 1161, 1097, 1046, 756, 738. [α]20D 
−69.2 ° (c 0.96, CHCl3); 1H NMR (400 MHz; CDCl3) δH 0.98 (3 H, s), 1.22 (3 H, d, J 6.0 Hz), 2.85-
2.94 (1 H, m), 3.01 (1 H, d, J 10.8 Hz), 3.68 (1 H, dd, J 7.6, 9.6 Hz), 3.86 (1 H, d, J 11.2 Hz), 4.20 (1 
H, dd, J 6.4, 7.6 Hz), 7.32-7.46 (7 H, m), 7.74-7.79 (1 H, m); 13C NMR (100 MHz; CHCl3) δC 15.9, 
30.5, 52.9, 59.7, 71.7, 97.5, 121.8, 125.9, 127.6, 127.7, 128.1, 128.7, 129.0, 129.3, 134.9, 136.9, 
142.4; m/z found for [M+H]+ 266.1542; [C18H19NO+H]+ requires 266.1539.  
 
(aS,3S,13bR)-13b-Methyl-3-isopropyl-2,3-dihydro-13bH-dibenz[c,e]oxazolo[3,2-a]azepine 25  
 (2S)-2-(2’-Iodobenzylamino)-3-methyl-butan-1-ol 21 (1.30 g, 4.09 mmol) and 2-acetyl 
phenylboronic acid (2.01 g, 12.3 mmol, 3 equiv.) were treated using general procedure B to yield the 
product (0.54 g, 1.90 mmol, 47%); νmax(film) /cm-1 3419, 2954, 2871, 1459, 1365, 1213, 1160, 1043, 
756, 730. [α]20D – 98.8 ° (c 1.21, CHCl3). 1H NMR (400 MHz; CDCl3) δH 0.96 (3 H,s), 0.99 (6 H, d, 
J 6.8 Hz), 1.88 (1 H, octet, J 6.8 Hz), 2.82 (1 H, q, J 6.0 Hz), 3.24 (1 H, d, J 11.2 Hz), 3.74 (1 H, d, J 
11.2 Hz), 3.86 (1 H, dd, J 6.0, 8.0 Hz), 4.02 (1 H, dd, J 7.0, 8.0 Hz), 7.34-7.37 (2 H, m), 7.38-7.43 (3 
H, m), 7.44-7.48 (2 H, m), 7.69-7.74 (1 H, m); 13C NMR (100 MHz; CHCl3) δC 17.1, 19.6, 30.2, 
30.5, 54.3, 65.8, 70.1, 98.2, 125.2, 127.6, 127.90, 127.91, 128.0, 128.3, 129.1, 135.8, 137.4, 140.5, 
142.1; m/z found for [M+H]+: 294.1857 [C20H23NO+H]+ requires 294.1852.  
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(aR,3R,13bS)-13b-Methyl-3-benzyl-2,3-dihydro-13bH-dibenz[c,e]oxazolo[3,2-a]azepine 26  
 (2R)-2-(2’-Iodobenzylamino)-3-phenyl-propan-1-ol 22 (1.00 g, 2.70 mmol) and 2-acetyl 
phenylboronic acid (1.34 g, 8.20 mmol, 3 equiv.) were treated using general procedure B to yield the 
product (0.51 g, 1.60 mmol, 60%); (νmax(film) /cm-1 2926, 1493, 1452, 1365, 1215, 1158, 1069, 
1043, 761, 738, 700. [α]20D −130.1° (c 0.99, CHCl3); 1H NMR (500 MHz; CDCl3) δH 0.93 (3 H, s), 
2.60-2.67 (1 H, m), 2.99-3.06 (2 H, m), 3.09 (1 H, d, J 11 Hz), 3.66 (1 H, d, J 11 Hz), 3.75 (1 H, t, J 
7.5 Hz), 3.93 (1 H, dd, J 6.5, 8.0 Hz). 7.11-7.16 (3 H, m), 7.18-7.24 (3 H, m), 7.24-7.27 (1 H, m), 
7.27- 7.32 (2 H, m), 7.32-7.39 (3 H, m), 7.63 (1 H, dd, J 1.5, 7.5 Hz); 13C NMR (125 MHz; CHCl3) 
δC 30.6, 39.7, 53.5, 66.2, 69.9, 98.1, 125.4, 126.4, 127.5, 127.8, 128.0, 128.5, 129.0, 129.1, 129.2, 
135.0, 137.1, 138.8, 140.1, 142.0; m/z found for [M+H]+: 342.1853; [C24H23NO+H]+ requires 
342.1858.  
 
(aS,3S,13bR)-13b-Methyl-3-benzyl-2,3-dihydro-13bH-dibenz[c,e]oxazolo[3,2-a]azepine 27  
 (2S)-2-(2’-Iodobenzylamino)-3-phenylpropan-1-ol 23 (1.00 g, 2.70 mmol) and 2-acetyl 
phenylboronic acid (1.34 g, 8.20 mmol, 3 equiv.) were treated using general procedure B to yield the 
product (0.27 g, 0.80 mmol, 30%); νmax(film) /cm-1 2926, 1493, 1452, 1365, 1215, 1158, 1069, 1043, 
761, 738, 700. [α]20D +130.9° (c 1.10, CHCl3). 1H NMR (400 MHz; CDCl3) δH 1.01 (3 H, s), 2.68-
2.76 (1 H, m), 3.07-3.19 (3 H, m), 3.75 (1 H, d, J 10.8 Hz), 3.83 (1 H, t, J 7.6 Hz), 4.02 (1 H, dd, J 
6.2, 7.6 Hz), 7.20-7.26 (3 H, m), 7.27-7.33 (3 H, m), 7.34-7.41 (3 H, m), 7.42-7.48 (3 H, m), 7.68-
7.72 (1 H, m); 13C NMR (100 MHz; CHCl3) δC 30.7, 39.7, 53.6, 66.3, 70.0, 98.2, 125.5, 126.5, 
127.6, 127.9, 128.0, 128.6, 129.1, 129.2, 129.3, 135.0, 137.1, 138.9, 140.1, 142.1; m/z [M+H]+: 
342.1853; [C24H23NO+H]+ requires 342.1858.  
 
(aS,3S,13bR)-3,13b-Dimethyl-2,3-dihydro-13bH-dibenz[c,e]oxazolo[3,2-a]azepin-5-ium 
tetraphenylborate salt 28  
Compound 24 (0.21 g, 0.80 mmol) in dichloromethane (2 mL) and N-bromosuccinimide (0.29 g, 
1.60 mmol, 2 equiv.) were treated using general procedure C to yield the product (0.20 g, 0.59 mmol, 
74%); νmax(film) /cm-1 2965, 1704, 1652, 1558, 1259, 1184, 1102, 1017, 763, 615. [α]20D 107.6 ° (c 
10.3, CHCl3); 1H NMR (500 MHz; d6-acetone) δH 1.56 (3 H, s), 1.90 (3 H, d, J 6.8 Hz), 4.48 (1 H, 
dd, J 2.9, 9.5 Hz), 4.54 (1 H, dd, J 5.3 & 9.5 Hz), 4.96-5.03 (1 H, m), 6.74-6.78 (4 H, m), 6.91 (8 H, 
t, J 7.4 Hz), 7.31-7.35 (8 H, m), 7.71 (1 H, dt, J 1.5, 7.5 Hz), 7.76 (1 H, dt, J 1.4, 7.5 Hz), 7.84-7.89 
(2 H, m), 7.91 (1 H, dd, J 1.1, 7.6 Hz), 8.10 (1 H, dt, J 1.2, 7.4 Hz),  8.16-8.20 (2 H, m), 9.67 (1 H, 
s); 13C NMR (125 MHz; d6-acetone) δC 19.7, 23.4, 65.8, 71.5, 100.4, 122.3, 124.6, 126.0 (q, 3 Hz), 
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129.9, 131.4, 131.5, 131.7, 132.6, 134.6, 136.0, 137.0, 137.9, 139.3, 143.1, 164.4, 164.8, 165.1, 
165.5, 165.7; m/z found for iminium cation: 264.1385; C18H18NO+ requires 264.1383.  
 
(aS,3S,13bR)-13b-Methyl-3-isopropyl-2,3-dihydro-13bH-dibenz[c,e]oxazolo[3,2-a]azepin-5-ium 
tetraphenylborate salt 29  
Compound 25 (0.54 g, 1.90 mmol) in dichloromethane (2 mL) and N-bromosuccinimide (0.68 g, 
3.80 mmol, 2 equiv.) were treated using general procedure C to yield the product (0.57 g, 1.50 mmol, 
81%); νmax(film) /cm-1 3055, 2998, 1639, 1596, 1579, 1559, 1479, 1425, 1377, 1184, 1031, 734. 
[α]20D +236.8 ° (c 2.0, CHCl3); 1H NMR (500 MHz; d6-acetone) δH 1.24 (3 H, d, J 7.0 Hz), 1.26 (3 
H, d, J 7.0 Hz), 1.54 (3 H, s), 2.64 (1 H, sextet, J 7.0 Hz), 4.47 (1 H, dd, J 5.0, 10.0 Hz), 4.60 (1 H, 
tt, J 1.5, 6.5 Hz), 4.72 (1 H, dd, J 2.0, 10.0 Hz), 6.79 (4 H, t, J 7.2 Hz), 6.93 (8 H, t, J 7.5 Hz), 7.33-
7.37 (8 H, m), 7.73 (1 H, td, J 1.5, 7.5 Hz), 7.77 (1 H, td, J 1.5, 7.5 Hz), 7.83-7.87 (2 H, m), 7.92 (1 
H, dd, J 1.5, 7.5 Hz), 8.09 (1 H, td, J 1.5, 7.5 Hz), 8.14 (1 H, dd, J 1.5, 7.5 Hz), 8.18 (1 H, d, 7.5 Hz), 
9.50 (1 H, s); 13C NMR (125 MHz; d6-acetone) δC 17.8, 19.2, 22.2, 31.9, 67.4, 73.6, 100.3, 122.0, 
124.3, 125.6, 125.73, 125.75, 125.77, 125.80, 129.7, 131.0, 131.2, 131.4, 132.4, 134.4, 135.6, 
136.75, 136.76, 137.6, 139.2, 142.7, 164.1, 164.5, 164.9, 165.3, 166.2; m/z found for M+ (iminium 
cation) 292.1704; [C20H22NO]+  requires 292.1701.  
 
(aR,3R,13bS)-13b-Methyl-3-phenyl-2,3-dihydro-13bH-dibenz[c,e]oxazolo[3,2-a]azepin-5-ium 
tetraphenylborate salt 8  
Compound 9 (0.43 g, 1.32 mmol) in dichloromethane (2 mL) and N-bromosuccinimide (0.47 g, 2.64 
mmol, 2 equiv.) were treated using general procedure C to yield the product as a pair of 
diastereoisomers (0.27 g, 0.66 mmol, 50%); νmax(film) /cm-1 3055, 1709, 1641, 1596, 1579, 1557, 
1479, 1426, 1361, 1222, 731, 703. [α]20D – 9.2 ° (c 1.3, acetone). 1H NMR (500 MHz; d6-acetone) 
δH 1.65 (3 H, s), 4.85 (1 H, dd, J 5.0, 10.0 Hz), 4.89 (1 H, dd, J 6.5, 10.0 Hz), 5.79 (1 H, dt, J 1.0, 5.8 
Hz), 6.72-6.77 (4 H, m), 6.88 (8 H, t, J 7.5 Hz), 7.28-7.34 (8 H, m), 7.57-7.60 (3 H, m), 7.68-7.72 (2 
H, m), 7.72-7.75 (2 H, m), 7.80 (1 H, dt, J 1.5, 7.5 Hz), 7.90 (2 H, dt, J 1.5, 7.5 Hz), 7.95 (1 H, dd, J 
1.0, 8.0 Hz), 8.05 (1 H, dt, J 1.5, 8.0 Hz), 8.16 (1 H, d, J 7.5 Hz), 9.27 (1 H, d, J 1.5 Hz); 13C NMR 
(125 MHz; d6-acetone) δC 21.4, 71.08, 71.15, 99.8, 121.4, 124.0, 125.1 (q, J 3Hz), 128.6, 128.8, 
129.1, 129.9, 130.4, 130.6, 130.7, 130.9, 131.8, 135.6, 136.2 (q, J 1 Hz), 137.4, 142.5, 163.5, 163.9, 
164.3, 164.7, 165.7. m/z found for M+ (iminium cation) 326.1549; [C23H20NO]+ requires 326.1545.  
 
(aR,3R,13bS)-13b-Methyl-3-benzyl-2,3-dihydro-13bHdibenz[c,e]oxazolo[3,2-a]azepin-5-ium; 
tetraphenylborate salt 30  
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Compound 26 (0.26 g, 0.80 mmol) in dichloromethane (2 mL) and N-bromosuccinimide (0.29 g, 
1.60 mmol, 2 equiv.) were treated using general procedure C to yield the product (0.28 g, 0.66 mmol, 
82%); νmax(film) /cm-1 3051, 3013, 1642, 1598, 1581, 1557, 1481, 1426, 1381, 1183, 1031, 1016, 
767, 755, 716, 714. [α]20D – 30.3 ° (c 1.4, CHCl3); 1H NMR (500 MHz; d6-acetone) δH 1.59 (3 H, s), 
3.61 (2 H, dq, J 7.5, 13.5 Hz), 4.49 (1 H, dd, J 5.0, 10.0 Hz), 4.66 (1 H, dd, J 1.5, 10.0 Hz), 5.06-
5.13 (1 H, m), 6.76 (4 H, t, J 7.0 Hz), 6.91 (8 H, t, J 7.0 Hz), 7.30-7.35 (8 H, m), 7.44-7.52 (5 H, m), 
7.70 (1 H, td, J 1.5, 7.5 Hz), 7.71 (1 H, dd, J 1.5, 8.0 Hz), 7.75 (1 H, td, J 1.5, 7.5 Hz), 7.82 (1 H, td, 
J 1.0, 8.0 Hz), 7.85 (1 H, td, J 1.5, 7.5 Hz), 7.89 (1 H, dd, J 1.5, 8.0 Hz), 8.08 (1 H, td, J 1.5, 7.5 Hz), 
8.16 (1 H, d, J  7.5 Hz), 8.91 (1 H, s); 13C NMR (125 MHz; d6-acetone) δC 23.3, 40.2, 70.1, 70.5, 
100.9, 122.2, 124.4, 125.5, 125.98, 126.00, 126.02, 126.04, 128.9, 130.0, 130.3, 130.9, 131.4, 131.5, 
131.7, 132.7, 134.6, 135.3, 136.0, 137.04, 137.05, 138.0, 139.2, 143.0, 134.4, 164.8, 165.2, 165.5, 
165.8; m/z found for M+ (iminium cation) 340.1707; [C24H22NO]+ requires 340.17014.  
 
(aS,3S,13bR)-13b-Methyl-3-benzyl-2,3-dihydro-13bHdibenz[c,e]oxazolo[3,2-a]azepin-5-ium, 
tetraphenylborate salt 31  
Compound 27 (0.51 g, 1.60 mmol) in dichloromethane (5 mL) and N-bromosuccinimide (0.57 g, 
3.20 mmol, 2 equiv.) were treated using general procedure C to yield the product (0.62 g, 1.20 mmol, 
75%); νmax(film) /cm-1 3445, 2358, 1714, 1654, 1616, 1558, 1454, 1404, 1257, 1182, 1104, 744, 701, 
668;  [α]20D +15.0 ° (c 1.07, CHCl3); 1H NMR (400 MHz; d6-acetone) δH 1.58 (3 H, s), 3.58 (2 H, 
dq, J 7.6, 13.6 Hz), 4.45 (1 H, dd, J 5.2, 10.0 Hz), 4.62 (1 H, dd, J 1.2, 10.0 Hz), 4.98-5.06 (1 H, m), 
6.76 (4 H, t, J 7.2 Hz), 6.90 (8 H, t, J 7.6 Hz), 7.30-7.36 (8 H, m), 7.43-7.52 (5 H, m), 7.67 (1 H, dd, 
J 1.2, 7.6 Hz), 7.70 (1 H, td, J 1.6, 7.6 Hz), 7.75 (1 H, td, J 1.6, 7.6 Hz), 7.80 (1 H, td, J 1.2, 7.6 Hz), 
7.85 (1 H, td, J 1.6, 8.0 Hz), 7.88 (1 H, dd, J 1.6, 7.6 Hz), 8.06 (1 H, td, J 1.2, 8.0 Hz), 8.14 (1 H, d, J  
7.2 Hz), 8.84 (1 H, s); 13C NMR (125 MHz; d6-acetone) δC 23.4, 40.3, 70.1, 70.5, 101.0, 122.4, 
124.5, 125.5, 126.10, 126.12, 126.15, 126.18, 129.0, 130.1, 130.4, 131.0, 131.5, 131.6, 131.8, 132.8, 
134.7, 135.5, 137.13, 137.15, 139.3, 143.1, 164.3, 164.8, 165.8, 165.9; m/z found for M+ (iminium 
cation) 340.1701; [C24H22NO]+ requires 340.1701.  
 
1-Phenylcyclohexene oxide 24  
Isolated as a colourless oil:  νmax(neat)/cm-1 3083, 1602, 1495, 1445, 1359, 1248, 1174, 1133, 1078, 
1030, 993, 974; 1H NMR (300 MHz; CDCl3) δH 1.20-1.33 (1 H, m), 1.51-1.62 (3 H, m), 1.97-2.05 (2 
H, m), 2.16-2.18 (1 H, m), 2.24-2.31 (1 H, m), 3.10 (1 H, t, J = 2.0 Hz), 7.26-7.41 (5 H, m).  
 
1-Phenyldihydronaphthalene oxide 24  
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Isolated as a colourless crystalline solid:  νmax(neat)/cm-1 3087, 1601, 1493, 1284, 1176, 1158, 1094, 
1072, 1028; 1H NMR (300 MHz; CDCl3) δH 2.10 (1 H, td, J = 15.5 Hz, 5.6 Hz) 2.48-2.59 (1 H, m), 
2.76 (1 H, dd, J = 15.5 Hz, 5.5 Hz) 2.96-3.07 (1 H, m), 3.70 (1 H, d, J = 3.0 Hz), 7.09-3.29 (4 H, m), 
7.45-7.60 (5 H, m). HPLC conditions-hexane/2-propanol (90:10), oven temp 20 °C, column Chiracel 
OD-H 01 250 × 4.6 mm, 5 μm particle size, flow rate 1 mL/min, 254 nm: tr-4.51 min (–)-(1S,2R), 
5.94 min (+)-(1R,2S).  
 
(E)-Stilbene oxide 24  
Isolated as a colourless crystalline solid: νmax(neat)/cm-1 3081, 1776, 1602, 1485, 1336, 1155, 1074, 
1042, 953; 1H NMR (400 MHz; CDCl3) δH 3.87 (2 H, s), 7.29-7.39 (10 H, m); δC (75 MHz; CDCl3) 
63.3, 126.0, 128.6, 129.3, 137.6. HPLC conditions-hexane/2-propanol (80:20), oven temp 20 °C, 
column Chiracel OD-H 01 250 × 4.6 mm, 5 μm particle size, flow rate 1 mL/min, 254 nm: tr-4.98 
min (–)-(1S,2S), 6.54 min (+)-(1R,2R).  
 
Dihydronaphthalene oxide 8  
Isolated as a colourless oil:  νmax(neat)/cm-1 3058, 3028, 2931, 2850, 1602, 1492, 1314, 1129, 1088, 
1031, 965; 1H NMR (400 MHz; CDCl3) δH 1.65-1.84 (1 H, m), 2.33-2.42 (1 H, m), 2.52 (1 H, dd, J 
= 15.5 Hz, 5.5 Hz), 2.67-2.85 (1 H, m), 3.71-3.80 (1 H, m), 3.81-3.89 (1 H, m), 7.05 (1 H, d, J = 7.2 
Hz), 7.18-7.35 (2 H, m), 7.40 (1 H, d, J = 7.1 Hz).  
 
Triphenylethylene oxide 8  
Isolated as a colourless crystalline solid:  νmax(neat)/cm-1 3061, 3031, 2956, 2924, 2857, 1604, 1595, 
1498, 1471, 1448, 1262, 1220, 741, 699; 1H NMR (400 MHz; CDCl3) δH 4.42 (1 H, s), 7.13- 5.50 
(15H, m). HPLC conditions-hexane/2-propanol (90:10), oven temp 20 °C, column Chiracel OD-H 
01 250 × 4.6 mm, 5 μm particle size, flow rate 1 mL/min, 254 nm: tr – 4.26 min (+)-(S), 7.47 min (–
)-(R).  
 
Crystallography  
For 9 and 27 diffraction data were collected at 150(2)K and corrections were made for absorption, 
Lorentz, and polarization factors. Both structures were solved by direct methods and were routine in 
nature. The absolute structures could not be determined reliably from the diffraction data, so were set 
from unchanging chiral centres. For 9: C23H21NO, M = 327.41, monoclinic, P21, a = 8.4016(5), b = 
9.9253(6), c = 10.5431(7) Å, β = 97.2928(9)°, V = 872.06(9) Å3, Z = 2, colourless crystal, 0.32 × 
0.29 × 0.10 mm3, Dcalc = 1.247 g/cm3, µ(Mo-Kα) = 0.076 mm–1, 9089 data measured, Rint = 0.020, 
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wR2 = 0.090 for all 4258 unique data, R1 = 0.037 for 3932 data with F2 ≥ 2σ(F2). For 27: C24H23NO, 
M = 341.43, monoclinic, P21, a = 8.5648(4), b = 9.8551(5), c = 11.1777(5) Å, β = 98.4207(7)°, V = 
933.30(8) Å3, Z = 2, colourless crystal, 0.52 × 0.38 × 0.36 mm3, Dcalc = 1.247 g/cm3, µ(Mo-Kα) = 
0.073 mm–1,11151 data measured, Rint = 0.022, wR2 = 0.119 for all 5541 unique data, R1 = 0.044 for 
4987 data with F2 ≥ 2σ(F2). CCDC 1400420-1400421 contain supplementary crystallographic data 
in cif format. These data can be obtained free of charge via 
www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge, CB2 
1EZ, UK. Fax +44 1223 336033, e-mail: deposit@ccdc.cam.ac.uk.). 
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